These Analysts Slash Their Forecasts On Altimmune Following Q2 Results
1. Altimmune reported a smaller-than-expected quarterly loss. 2. Company sales were $5,000K, showing market resilience. 3. Pemvidutide trial results indicate strong progress in weight loss. 4. Analysts have adjusted price targets while maintaining Buy ratings. 5. Altimmune shares rose 5.7% following the earnings report.